CEP85L::ROS1 (6q22)
Oncogenic mechanisms
Constitutive activation of ROS1 tyrosine kinase activity
Targeted therapy
Crizotinib
Entrectinib
Tumor type
Glioblastoma multiforme
angiosarcoma
Highly cited references
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 23637631 | 2013 | Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types. | 98 |
| 34875133 | 2022 | Detection of gene mutations and gene-gene fusions in circulating cell-free DNA of glioblastoma patients: an avenue for clinically relevant diagnostic analysis. | 61 |
| 27153396 | 2016 | Analyzing Somatic Genome Rearrangements in Human Cancers by Using Whole-Exome Sequencing. | 57 |
| 30171048 | 2018 | Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. | 51 |
| 28912153 | 2017 | Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures. | 33 |
| 36923435 | 2023 | Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib. | 24 |
Bibliography
| Pubmed ID | Publication Year | Title | Authors |
|---|---|---|---|
| 30171048 | 2018 | Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. | Davare MA, et al |
| 23637631 | 2013 | Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types. | Giacomini CP, et al |
| 24261984 | 2013 | Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data. | Shah N, et al |
| 25500544 | 2015 | The landscape and therapeutic relevance of cancer-associated transcript fusions. | Yoshihara K, et al |
| 25204415 | 2014 | The landscape of kinase fusions in cancer. | Stransky N, et al |
